Benjamin F. Edwards & Company’s Lipocine LPCN Stock Holding History

Benjamin F. Edwards & Company’s Portfolio LPCN Stock Details LPCN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-88	Closed	-$1K	–	1860
2022 Q4	$1K	Hold	88	–	–	﹤0.01%	1790
2022 Q3	$1K	Hold	88	–	–	﹤0.01%	1765
2022 Q2	$1K	Hold	88	–	–	﹤0.01%	1755
2022 Q1	$2K	Hold	88	–	–	﹤0.01%	1663
2021 Q4	$1K	Hold	88	–	–	﹤0.01%	1668
2021 Q3	$2K	Hold	88	–	–	﹤0.01%	1636
2021 Q2	$2K	Hold	88	–	–	﹤0.01%	1627
2021 Q1	$2K	Hold	88	–	–	﹤0.01%	1623
2020 Q4	$2K	Hold	88	–	–	﹤0.01%	1537
2020 Q3	$2K	Hold	88	–	–	﹤0.01%	1578
2020 Q2	$2K	Hold	88	–	–	﹤0.01%	1584
2020 Q1	$1K	Hold	88	–	–	﹤0.01%	1661
2019 Q4	$1K	Hold	88	–	–	﹤0.01%	1822
2019 Q3	$4K	Hold	88	–	–	﹤0.01%	1631
2019 Q2	$3K	Hold	88	–	–	﹤0.01%	1744
2019 Q1	$3K	Hold	88	–	–	﹤0.01%	1568
2018 Q4	$2K	Buy	+88	New	+$2.04K	﹤0.01%	1603

Other funds holding LPCN

EWA

EP Wealth Advisors Torrance, California $20.3B AUM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wealth Effects Boston, Massachusetts $282M AUM 62.81% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

KAS

Kestra Advisory Services Austin, Texas $26.4B AUM 21.05% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Benjamin F. Edwards & Company's LPCN Position: Q1 2023 in Review

Benjamin F. Edwards & Company sold out of Lipocine (LPCN) in Q1 2023, closing a stake of 88 shares — an estimated $1K sold.

Benjamin F. Edwards & Company first reported a position in LPCN in Q4 2018 and held it in 17 quarters. The position peaked at $4K in Q3 2019. 45 funds tracked by Wall St. Rank hold LPCN as of Q1 2023.

Benjamin F. Edwards & Company reported no remaining Lipocine position as of Q1 2023 after selling out during the quarter.
Benjamin F. Edwards & Company sold 88 Lipocine shares in Q1 2023, an estimated $1K.
Benjamin F. Edwards & Company first reported a position in Lipocine in Q4 2018 and held it in 17 quarters.
Benjamin F. Edwards & Company's Lipocine position peaked at $4K in Q3 2019.
45 funds tracked by Wall St. Rank held Lipocine as of Q1 2023.

Based on Benjamin F. Edwards & Company's 13F filing for Q1 2023, filed 27 Apr 2023.